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Abstract
Background—Prior studies on intake of linoleic acid (LA), the predominant n-6 fatty acid, and 
coronary heart disease (CHD) risk have generated inconsistent results. We performed a systematic 
review and meta-analysis of prospective cohort studies to summarize the evidence regarding the 
relation of dietary LA intake and CHD risk.
Methods and Results—We searched MEDLINE and EMBASE databases through June, 2013 
for prospective cohort studies that reported the association between dietary LA and CHD events. 
In addition, we utilized unpublished data from cohort studies in a previous pooling project. We 
pooled the multivariate-adjusted relative risk (RR) comparing the highest with the lowest 
categories of LA intake using fixed-effect meta-analysis. We identified 13 published and 
unpublished cohort studies with a total of 310,602 individuals and 12,479 total CHD events 
including 5,882 CHD deaths. Comparing the highest to the lowest category, dietary LA was 
associated with a 15% lower risk of CHD events (pooled RR, 0.85; 95% confidence intervals 
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(95% CI): 0.78–0.92; I2=35.5%) and a 21% lower risk of CHD deaths (pooled RR, 0.79; 95% CI, 
0.71–0.89; I2=0.0%). A 5% of energy increment in LA intake replacing energy from saturated fat 
intake was associated with a 9% lower risk of CHD events (RR, 0.91; 95% CI, 0.86–0.96) and a 
13% lower risk of CHD deaths (RR, 0.87; 95% CI, 0.82–0.94).
Conclusion—In prospective observational studies, dietary LA intake is inversely associated with 
CHD risk in a dose-response manner. These data provide support for current recommendations to 
replace saturated fat with polyunsaturated fat for primary prevention of CHD.
Keywords
Linoleic acid; coronary heart disease; meta-analysis
INTRODUCTION
The effects of dietary fat intake on primary prevention of coronary heart disease (CHD) 
have been a long standing interest.1 Greater intakes of trans-fat and saturated fat in 
comparison to polyunsaturated fatty acids (PUFAs) are associated with increased risk of 
CHD.2 Therefore, substitution of PUFAs for saturated fatty acids (SFAs) has been 
recommended to reduce CHD risk.3,4 Previous studies have investigated the effects of n-3 
PUFAs (including the long-chain n-3 and alpha-linolenic acid) on CHD risk,5,6 but the 
relation between intake of n-6 PUFAs and risk of CHD has been less extensively studied.
Some observational studies and many controlled feeding studies have documented that 
linoleic acid (LA), the predominant n-6 PUFA in the Western diet and primarily from 
vegetable oils and nuts (e.g. sunflower, safflower, soya, corn and walnuts), reduces major 
risk factors for CHD. Higher LA intake reduces LDL cholesterol,7–10 promotes insulin 
sensitivity,7,11 and reduces risk of hypertension.12,13 Therefore, substitution of dietary n-6 
PUFAs for SFAs has long been recommended to prevent CHD.1 However, concerns have 
been raised about higher LA consumption being harmful for heart health because of 
potential pro-inflammatory and thrombogenic properties.14–17 LA can be elongated to 
arachidonic acid (AA) and subsequently synthesized to a variety of pro-inflammatory 
eicosanoids, which may increase CHD risk.18–20 However, this speculation is not supported 
by randomized controlled feeding studies, in which dietary intake of LA was not found to 
increase inflammatory markers including C-reactive protein, cytokines, fibrinogen, soluble 
vascular adhesion molecules, plasminogen activator inhibitor type 1, or tumor necrosis 
factor-α.21
Recently, a secondary analysis of a small clinical trial conducted in the 1960s suggested that 
substituting high-LA safflower oil for saturated fat increased cardiovascular mortality.17 In 
addition, the authors conducted an updated meta-analysis of LA intervention trials (high LA 
oils without n-3 fatty acids such as corn oil and safflower oil), which showed non-significant 
trends toward increased risks of CHD death, whereas the trials using high LA oils with n-3 
fatty acids (e.g., soybean oil) showed opposite trends.17 However, these trials were small 
with limited power, and most of them were conducted in patients with existing heart 
diseases. More recently, Chowdhury et al.22 reported no significant association between n-6 
PUFAs and coronary events in a meta-analysis, and concluded that the evidence did not 
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support current recommendations to replace SFAs with PUFAs. However, this analysis was 
based on a limited number of studies with some erroneous data. Moreover, the meta-analysis 
could not compare LA with saturated fat or any other specific macronutrient 
(annals.org.ezp-prod1.hul.harvard.edu/article.aspx?articleid=1846638 comments). To 
address the role of LA in primary prevention of CHD using published data on LA and CHD 
events as well as data from unpublished cohort studies, we performed a systematic review 
and meta-analysis of prospective cohort studies to examine the association between dietary 
LA intake and CHD endpoints in generally healthy populations.
SUBJECTS AND METHODS
Study Strategy
We followed the checklist of Meta-analysis Of Observational Studies in Epidemiology 
(MOOSE) for background, design, analysis and interpretation.23 We conducted a systematic 
literature search of two databases, MEDLINE and EMBASE, related articles, hand-
searching of key journals and references and direct author contacts for all cohort studies 
describing the association of dietary LA intake with incident CHD outcomes, which include 
myocardial infarction (MI), ischemic heart disease, coronary artery bypass graft, sudden 
cardiac arrest, acute coronary syndrome and CHD deaths. Our search terms combined the 
exposure (LA) with various CHD outcomes, and the full details on the search strategy are 
presented in the Supplemental Material. Searches included the earliest available online 
indexing year through to June 30, 2013.
Selection of Articles
The titles and abstracts of the identified studies were screened by one investigator (M.S.F.) 
for potentially relevant articles. Two investigators (M.S.F. and M.D.) independently 
assessed the full-text of those selected articles to determine relevant articles for inclusion; 
any discrepancies were resolved by consultation with the third investigator (F.B.H.). Studies 
were included if they were prospective cohort studies that provided multivariate-adjusted 
risk estimates [relative risk (RR) or hazard ratio (HR)] for dietary LA consumption as the 
exposure and CHD endpoints. We excluded retrospective, cross-sectional or ecological 
studies, studies in non-adults (<19 years old), non-original papers (reviews, editorials, or 
letters), meeting abstracts and duplicated publications. We also excluded studies conducted 
in patients with known CHD at baseline. For multiple manuscripts that published from the 
same cohort, the most up-to-date analyses with highest number of outcomes were included 
in the meta-analysis.
The search strategy identified 8782 unique citations (Figure 1). After screening the titles and 
abstracts, 566 full-text articles were evaluated which 6 original articles were identified as 
being appropriate for inclusion in this meta-analysis.24–29 We also obtained permission from 
principal investigators of the cohort studies presented in the Pooling Project of Cohort 
Studies on Diet and Coronary Disease,4 to examine the association between LA intake and 
CHD risk and included these results in the meta-analysis. The characteristics of these cohort 
studies in the pooling project were described elsewhere in detail.4 Among 11 cohort studies 
included in Pooling Project of Cohort Studies on Diet and Coronary Disease, we used data 
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of the 6 cohort studies [Atherosclerosis Risk in Communities Study (ARIC); Finnish Mobile 
Clinic Health Study (FMC); Israeli Ischemic Heart Disease Study (IIHD); Iowa Women’s 
Health Study (IWHS); Västerbotten Intervention Program (VIP) and Women's Health Study 
(WHS)], to assess the association between LA and total CHD and CHD deaths.4 The results 
for associations of LA and CHD events have been previously published in Nurses’ Health 
Study (NHS), Health Professional Follow-up Study (HPFS) and Alpha-Tocopherol and 
Beta-Carotene Cancer Prevention Study (ATBC).26–28 Furthermore, the association between 
dietary n-6 fatty acid and coronary events was evaluated in 8139 men and 12,535 women in 
the Malmo Diet and Cancer Cohort study.30 The associations between LA and CHD events 
have been provided by the study investigators through personal correspondence. In addition, 
we included the results of three other previously published studies.24,25,29 In the NHS and 
HPFS, we updated the published analyses with longer follow-up: from 20 years in previous 
publications to 30 years in the NHS, and from 6 years to 24 years in the HPFS. In addition, 
we reanalyzed data in ATBC study to adjust for the confounding variables similar to other 
included cohort studies in this meta-analysis (Table 1). In studies where the results on LA 
were not published before or results were updated in this meta-analysis, the relative risks 
(RRs) with 95% confidence intervals (95% CIs) for the incidence of CHD events were 
calculated by Cox proportional hazards regression models with time in study (years) as the 
time metric. The multivariate model included total energy, age, smoking, body mass index, 
physical activity, education level, alcohol intake, hypertension, fiber intake, and percent of 
energy from SFAs, trans fat, monounsaturated fatty acids (MUFAs), alpha-linolenic acid 
(ALA), PUFAs other than LA and ALA, and protein intake. Due to lack of data on ALA and 
trans fat intakes in IIHD and MDC studies, we adjusted for PUFAs other than LA. In this 
model, the relative risk for LA represents its substitution for the same percent of energy 
from carbohydrate.31 We also estimated HRs of CHD for the substitution of SFAs by LA. 
To do this, we adjusted for percent of energy from carbohydrates instead of SFAs in the 
above multivariate model. The analyses were performed by SAS version 9.3 (SAS Institute 
Inc., Cary, NC).
Data extraction
Two investigators (M.S.F. and M.D.) independently extracted information on study 
characteristics (author, study name, country, and publication year), duration of follow-up 
(mean, median or maximum number of follow-up), sample size, CHD outcomes (specific 
endpoints), gender, subject age (mean or median), methods for assessing LA consumption, 
covariates in the statistical models, multivariable-adjusted risk estimates and precision (e.g., 
95% CIs, SEs, or P values). When more than one multivariable model was assessed or one 
article reported multiple RRs for different coronary outcomes, we extracted the RRs for the 
most specific coronary outcome event (according to the hierarchy: total CHD, CHD deaths, 
nonfatal CHD) with the largest number of adjustment variables.
Data synthesis
The included studies reported RRs or Hazard Ratios (HRs) of CHD events by categories of 
dietary LA intake, and RRs are assumed to be unbiased estimates of HRs when events are 
rare. Studies reported risk estimates based on various categories of LA intake (eg, tertiles, 
quartiles or quintiles), and we decided to use the RRs comparing the highest versus lowest 
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category. For a study29 that reported RRs without corresponding 95% CIs, standard errors 
for the RRs were estimated from SE=β/Zp where β is the regression coefficient for 1% 
increment of energy from LA and Zp is the value of a unit-normal test statistic 
corresponding to the p value.32
Forest plots were used to evaluate RRs and corresponding 95% CIs for specific studies. 
Overall RRs were calculated using fixed-effect models (Mantel-Haenszel method), and we 
also calculated random-effects models (DerSimonian and Laird method) as sensitivity 
analysis. Potential heterogeneity among studies was assessed using the I2 statistic, and the 
heterogeneity was further explored using stratified analysis and meta-regression method. 
Sources of heterogeneity included duration of follow-up (< or ≥ median follow-up years of 
all cohorts), age (< or ≥ median baseline age of all cohorts), sex (male, female, or both), 
repeated measures of intake and study quality score. The possibility of publication bias was 
evaluated by visual inspection of a funnel plot and the Begg's test.
Potential nonlinear relations were examined using restricted cubic spline models with 3 
knots at the 25th, 50th and 75th percentiles. We also carried out a dose-response meta-
analysis using generalized least-squares regression (2-stage GLST in Stata).33 Using 
information on risk estimate, standard error, median of LA intake, number of cases, person-
year of follow-up or number of subjects from all exposure categories, the log-linear dose-
response slope within each study was estimated and then pooled to derive an overall risk 
estimate. One study29 already reported risk estimates for linear differences in exposure, and 
data were added to the GLST model at the second stage. All analyses were performed using 
Stata version 12.0 (STATA Corp, College Station, TX), with a 2-tailed α of 0.05 as 
statistical significance.
RESULTS
Study characteristics
The characteristics of the 13 identified cohort studies are shown in Table 1. Three cohort 
studies (IWHS, IIHD and Multiple Risk Factor Intervention Trial (MRFIT)) did not report 
results for total CHD and four studies (Multinational Monitoring of Trends and 
Determinations in Cardiovascular Disease (MONICA), ARIC, FMC and VIP) reported 
results separately for men and women, thus 14 estimates were available for total CHD. Two 
studies (MONICA and Monitoring Project on Risk Factors for Chronic Diseases 
(MORGEN)) did not report results for CHD deaths and one study (FMC) reported results 
separately for men and women, thus 12 estimates were available for CHD deaths. The 
numbers of participants in each study ranged from 1643 to 84,564, with follow-up durations 
ranging from 5.3 to 30 years, comprising a total of 310,602 individuals and 12,479 cases of 
total CHD events and 5,882 CHD deaths. LA consumption varied substantially across 
studies, with the median intakes across studies ranging from 1.5 to 6.4 percent of energy 
(10th vs 90th percent range from 1.1 to 9.5 percent of energy) (Supplemental Tables S1–S4). 
Except for one study conducted in Israel, all other studies were from the North American (n 
=6) or European countries (n = 6). In all cohort studies, except for two studies (MONICA 
and MRFIT),24, 29 the RRs for LA can be interpreted as effects of substituting percent of 
energy intake from LA for the same percent of energy intake from carbohydrates. We were 
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able to estimate the effects of substituting percent of energy intake from LA for the same 
amount of energy from SFAs for all cohort studies except for MONICA, MORGEN and 
MRFIT.24, 25, 29
For unpublished and updated cohort studies, the RRs and 95% CIs across the quintiles of LA 
intake and total CHD and CHD deaths are shown in the Supplemental Tables S1–S4. Due to 
the small number of CHD events in ARIC study in women, FMC study in women, and VIP 
study in men and women and small number of CHD death in FMC study in women, WHS 
study, and VIP study in men, the RRs and 95% CIs across the tertiles of LA intake were 
provided.
Meta-analysis of LA and total CHD events
Across 10 cohort studies that examined the association between LA and total CHD events 
(14 estimates), LA consumption was inversely associated with risk of total CHD events. The 
fixed-effect summary of RR for comparing the highest with lowest category was 0.85 (95% 
CI, 0.78–0.92; Figure 2) with medium heterogeneity (I2 = 35.5%). This finding was similar 
using a random-effects model (RR, 0.86; 95% CI, 0.76–0.97).
The meta-regression analysis did not identify statistically significant sources of 
heterogeneity, including the mean age of the participants, gender, study duration, repeated 
measures of intake or study quality score (all P >0.10).
Meta-analysis of LA and CHD deaths
Among 11 cohort studies (12 estimates) that examined the association between LA and 
CHD deaths, higher LA intake was associated with a lower risk of CHD deaths. The fixed-
effect summary of RR for comparing the highest with lowest category was 0.79 (95% CI, 
0.71–0.89; Figure 3).
Dose-response meta-analyses
In the dose-response analysis, we found a linear association between LA intake and CHD 
events (P=0.91 for non-linearity; Figure 4) and CHD deaths (P=0.72 for non-linearity; 
Figure 5). An increment of 5% of energy intake from LA was associated with a 10% lower 
risk of CHD events (RR, 0.90; 95% CI, 0.85–0.94;I2 = 44.6%; Figure 6) and a 13% lower 
risk of CHD deaths (RR, 0.87; 95% CI, 0.81–0.93; Figure 7). Among 9 cohort studies (12 
estimates) that evaluated substitution of LA for carbohydrate, the risk estimate for 
substituting 5% energy intake from LA for carbohydrates was 0.90 (95% CI, 0.85–0.94;I2 = 
47.3%; Supplemental Figure S1) with a fixed-effect model and 0.89 (95% CI, 0.80–0.98) 
with a random-effects model. Among 8 cohort studies (11 estimates) that evaluated 
substitution of LA for SFA, the risk estimate for substituting 5% energy intake from LA for 
SFAs was 0.91 (95% CI, 0.87–0.96;I2 = 55.9%; Supplemental Figure S2) with a fixed-effect 
model and 0.90 (95% CI, 0.80–1.01) with a random-effects model. Substituting 5% energy 
intake from LA for the same amount of energy from carbohydrates was associated with an 
13% lower risk of CHD deaths (RR, 0.87; 95% CI, 0.81–0.94; Supplemental Figure S3) and 
an 13% lower risk of CHD deaths when substituting for the same amount of energy from 
SFAs (RR, 0.87; 95% CI, 0.82–0.94; Supplemental Figure S4).
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Publication bias
For dietary LA intake, visual inspection of a funnel plot (see Supplemental Figures S5 and 
S6) and Begg's test suggested no evidence of publication bias for either CHD events (P = 
0.25) or CHD deaths (P = 1.00).
DISCUSSION
This systematic review and meta-analysis support a significant inverse association between 
dietary LA intake, when replacing either carbohydrates or saturated fat, and risk of CHD. 
Our dose-response analyses identified a lower risk of both total CHD events and CHD 
deaths with increasing LA intake in a linear fashion. These associations were independent of 
traditional CHD risk factors and other dietary factors such as fiber and ALA.
An inverse association between intake of PUFAs and CHD was reported in a pooled 
analysis of 11 prospective cohort studies in the US, Europe and Israel.4 In that pooled 
analysis with a wide range of PUFA intake (from 1.7% to 10.6%), each 5% lower energy 
intake from SFAs and a concomitant higher energy from PUFAs was associated with 13% 
lower risk of coronary events and 26% lower risk of coronary death.4 Consistent with that 
analyses, our meta-analysis suggests that intake of LA, the predominant n-6 PUFA, has 
cardio-protective effects: a 5% increase in energy from LA, replacing SFAs, was associated 
with 9% lower risk of total CHD and 13% lower risk of CHD deaths. A comparison of our 
findings to those of clinical trials of PUFA consumption is also informative. In a meta-
analysis of eight RCTs, Mozaffarian et al.3 found that each 5% increase in energy from 
PUFAs, replacing SFAs, would reduce occurrence of coronary events by 10%.
An inverse association between LA and CHD has also been seen in most previous studies of 
LA biomarkers and CHD events. In a meta-analysis of 22 studies including case-control and 
prospective cohort data, blood/tissue LA concentrations were inversely associated with non-
fatal CHD endpoints.34 Even in a population with high PUFAs intake (mean intake 10.1% of 
energy) and very high LA adipose tissue content (25.6% of adipose tissue composition), an 
inverse association was found between adipose LA and acute MI after controlling for other 
n-6 PUFAs.35 Concerns about recommendations for diets high in LA have been based on the 
assumption that AA produced from metabolism of LA is the main precursor of eicosanoids 
with inflammatory and thrombogenic properties such as prostaglandin E2, thromboxane A2 
and Leukotriene B4.15,36 However, conversion of LA to AA is tightly controlled, variations 
in dietary LA intake do not appreciably modify tissue AA content;37,38 and adipose tissue 
AA concentrations are not associated with LA dietary intake or adipose tissue levels of 
LA.19,20 Also, some molecules that reduce inflammation and thrombosis such as 
prostacyclin, epoxyeicosatrienoic acids and lipoxin A4 are produced from AA.39,40 In an 
Italian adult population, higher plasma levels of AA were associated with lower plasma 
levels of pro-inflammatory and higher levels of anti-inflammatory markers.41 Although in 
several studies adipose tissue content of AA was positively correlated with risk of MI,1920 
this was not supported in a meta-analysis of 20 prospective and case-control studies where 
tissue AA was unrelated to either non-fatal or fatal CHD outcomes.34 Furthermore, 
consumption of an AA-enriched oil did not increase urinary and plasma AA metabolites or 
blood biomarkers of cardiovascular, inflammatory or allergic diseases.42 Independent of 
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effects on AA, diets high in n-6 PUFAs, might decrease beneficial effects of n-3 PUFAs on 
CHD risk by competition in elongation and desaturation pathways.43,44 Because of multiple, 
potentially competing effects on many metabolic pathways, the effects of LA on heart 
disease risks are difficult to predict by these mechanistic considerations. A diet high in LA is 
considered to increase lipid susceptibility to free radical oxidation and lipid peroxidation 
that may play a role in etiology of cancer.45 However, in the extensive literature on this 
topic, including many prospective studies and meta-analyses, there is little evidence that 
higher intake of LA is associated with an increased risk of cancer in prospective 
studies.46–48
Recommendations to reduce LA in the diet are based on minimal direct evidence.14–17 
Ramsden et al.17 investigated the effects of increasing LA alone and LA in combination 
with ALA on CHD mortality in men with recent coronary events in a single-blinded, 
randomized controlled trial that was conducted in the 1960’s in Australia. They suggested 
that n-6 LA alone increased the risk of CHD mortality. However, the study sample size was 
very small (n = 221) and the 95% CIs for the estimates were wide (RR, 1.74; 95% CI, 1.04–
2.91). The duration of the study was also short (39 months). In addition, partial 
hydrogenation of vegetable oils was a common practice in the 1960’s and the results may 
have been confounded by trans fat in the special margarines high in LA. Also, by replacing 
dietary fats as much as possible with oils high in LA but with little n-3 PUFAs, any adverse 
effects may have been due to low n-3 PUFAs rather than high LA.
Potential limitations to this study should be considered. As in any meta-analysis, publication 
bias is possible. However, significant publication bias was not indicated through visual 
inspection of funnel plots and Begg’s test. We cannot exclude the possibility of residual 
confounding due to the observational nature of the included studies. However, most of the 
studies adjusted for major CHD risk factors and other dietary sources of energy. In most of 
the studies, diet was assessed using a FFQ, thus measurement errors may be introduced by 
the under- or over-reporting of the amounts of food groups usually eaten per day. In 
addition, since FFQs used in some studies did not query brand names of margarine, cooking 
oils, salad dressings, and other foods containing linoleic acid, the intake levels of LA may be 
underestimated in these studies.
Our analysis has several strengths. Our comprehensive search methods, personal contacts 
with authors and experts, and inclusion of unpublished data in several cohorts (ARIC, FMC, 
IIHD, IWHS, VIP, WHS and MDC) as well as updated analyses in some cohorts (NHS, 
HPFS, and ATBC) minimized misclassification and potential for publication bias. We 
limited our analysis to prospective cohort studies to minimize the influence of recall and 
selection biases that are common in case-control studies. Also, most studies adjusted for 
potential CHD risk factors and other types of dietary fat. Despite variations in LA 
measurement methods, population characteristics, study design, and specific outcomes 
evaluated in the included cohort studies, there was low to moderate heterogeneity across 
studies, which supports the validity of the pooled results. In our meta-analysis, except for the 
MONICA and MRFIT studies,24,29 all other cohort studies adjusted for energy from other 
fat components (SFAs, trans fat, MUFAs, and PUFAs other than LA). It is worth noting that 
the inverse association between LA and CHD was independent of ALA intake. In these 
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analyses, the association between LA and CHD was compared to that for CHD with both 
carbohydrate and saturated fat intakes. Other advantages included the ability to evaluate the 
association of LA intake and CHD events in different populations with different diets 
including large variations in intakes of LA.
CONCLUSIONS
This current systematic review and meta-analysis of prospective cohort studies of LA 
consumption provides robust evidence that higher LA intake is associated with lower risk of 
CHD in a dose-response fashion. These data support current recommendations to replace 
saturated fat with LA for primary prevention of CHD in the general population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Search, screening and selection process of prospective cohort studies of dietary linoleic acid 
and risk of coronary heart disease.
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Figure 2. 
Dietary intake of linoleic acid and relative risk of total coronary heart disease events 
(highest category versus lowest category). The relative risk was pooled by using fixed 
effects meta-analysis.
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Figure 3. 
Dietary intake of linoleic acid and relative risk of coronary heart disease deaths (highest 
category versus lowest category). The relative risk was pooled by using fixed effects meta-
analysis.
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Figure 4. 
Dose-response analysis for curvilinear association between dietary intake of linoleic acid 
and total coronary heart disease events. P=0.91 for non-linearity relationship, indicating a 
linear relationship.
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Figure 5. 
Dose-response analysis for curvilinear association between dietary intake of linoleic acid 
and coronary heart disease deaths. P=0.72 for non-linearity relationship, indicating a linear 
relationship.
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Figure 6. 
Two-stage dose-response meta-analysis of each 5% energy increment of dietary intake of 
linoleic acid and relative risk of total coronary heart disease events. The relative risk was 
pooled by using fixed effects meta-analysis.
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Figure 7. 
Two-stage dose-response meta-analysis of each 5% energy increment of dietary intake of 
linoleic acid and relative risk of coronary heart disease deaths. The relative risk was pooled 
by using fixed effects meta-analysis.
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